Immuno Suppressants

Immunosuppressants are essential in ophthalmology for controlling immune-mediated ocular diseases and preventing graft rejection after corneal transplantation. The immune system normally protects the body from harmful foreign molecules. However, in transplantation and autoimmune eye disorders, immune activation can damage healthy ocular tissues. Modern immunosuppressive therapy focuses on selectively altering lymphocyte function, particularly T-cell activation, while minimizing systemic toxicity.

The immune activation cascade follows a three-signal model:

• Signal 1: Antigen recognition at the CD3 receptor complex on T cells

• Signal 2: Costimulation via CD80/CD86 on antigen-presenting cells binding to CD28

• Signal 3: IL-2–mediated T-cell proliferation through mTOR activation

Immunosuppressive drugs act by interfering with cytokine production, blocking T-cell proliferation, or targeting immune surface proteins with antibodies.

I. Selective Inhibitors of Cytokine Production and Function

These drugs primarily reduce IL-2 production or action, thereby suppressing T-cell activation.

1. Cyclosporine

Ophthalmic Uses

• Moderate to severe dry eye disease

• Vernal and atopic keratoconjunctivitis

• Prevention of corneal graft rejection

• Steroid-sparing therapy in chronic ocular inflammation

Key Points

• Available as topical ophthalmic emulsion

• Minimal systemic absorption in eye use

• Burning sensation is common initially

• Long-term therapy improves tear production

Adverse Effects (Systemic Use)

• Nephrotoxicity (dose dependent)

• Hypertension and hyperlipidemia

• Gingival hyperplasia and hirsutism

2. Tacrolimus

Tacrolimus is another calcineurin inhibitor but more potent than cyclosporine. It binds to FK-binding protein (FKBP-12) and inhibits calcineurin, leading to decreased IL-2 production and reduced T-cell activation.

Ophthalmic Uses

• Severe vernal keratoconjunctivitis

• Atopic keratoconjunctivitis

• Steroid-resistant anterior uveitis

• Ocular surface autoimmune disease

Key Points

• Used as topical ointment or compounded drops

• Strong steroid-sparing effect

• Preferred in refractory allergic eye disease

Adverse Effects

• Neurotoxicity (systemic use)

• Nephrotoxicity

• May cause alopecia (unlike cyclosporine)

3. mTOR Inhibitors (Sirolimus & Everolimus)

Sirolimus and Everolimus inhibit mTOR (mammalian target of rapamycin), which is responsible for Signal 3 in T-cell activation. Unlike calcineurin inhibitors, these drugs do not reduce IL-2 production but block cellular response to IL-2, preventing progression of T cells from G1 to S phase of the cell cycle.

Ophthalmic Relevance

• Severe non-infectious uveitis (systemic therapy)

• Refractory ocular inflammatory diseases

• Adjunct in high-risk transplant patients

Key Points

• Often combined with other immunosuppressants

• Long half-life (sirolimus allows once-daily dosing)

• Synergistic with calcineurin inhibitors

Adverse Effects

• Hyperlipidemia

• Delayed wound healing

• Leukopenia and thrombocytopenia

4. Costimulation Blocker – Belatacept

Clinical Role

• Maintenance immunosuppression in transplant patients

• Alternative to calcineurin inhibitors

Key Points

• Administered intravenously

• Monthly dosing improves compliance

• Avoids long-term nephrotoxicity of calcineurin inhibitors

Major Risk

• Increased risk of post-transplant lymphoproliferative disorder

II. Immunosuppressive Antimetabolites

These agents inhibit lymphocyte proliferation by blocking purine synthesis.

5. Azathioprine

Ophthalmic Uses

• Chronic uveitis

• Ocular cicatricial pemphigoid

• Severe scleritis

Key Points

• Used as steroid-sparing agent

• Requires blood count monitoring

• Dose reduction needed with allopurinol

Major Toxicity

• Bone marrow suppression

6. Mycophenolate Mofetil

Ophthalmic Uses

• Non-infectious uveitis

• Posterior uveitis

• Autoimmune ocular inflammation

Key Points

• Better safety profile than azathioprine

• Rapid oral absorption

• Often replaces azathioprine in modern therapy

Adverse Effects

• Gastrointestinal upset (diarrhea, nausea)

• Increased risk of CMV infection at high doses

III. Monoclonal and Polyclonal Antibodies

These drugs target specific immune surface proteins to suppress T-cell activity.

7. Antithymocyte Globulin (ATG)

Antithymocyte globulin consists of polyclonal antibodies directed against T lymphocytes. It causes complement-mediated destruction and apoptosis of T cells, resulting in lymphopenia.

Uses

• Severe graft rejection

• Steroid-resistant rejection episodes

Adverse Effects

• Fever and chills

• Leukopenia

• Increased infection risk

8. Basiliximab

Basiliximab is a chimeric monoclonal antibody targeting CD25 (IL-2 receptor α-chain). By blocking IL-2 binding, it prevents T-cell proliferation.

Clinical Role

• Prophylaxis of acute rejection

• Combined with other immunosuppressive agents

Key Points

• IV administration

• Two-dose regimen

• Generally well tolerated

IV. Corticosteroids in Ophthalmic Immunosuppression

Corticosteroids remain a cornerstone of ocular immunosuppressive therapy. They reduce lymphocyte populations and regulate gene transcription involved in inflammatory responses.

Ophthalmic Uses

• Uveitis

• Scleritis

• Optic neuritis

• Post-transplant inflammation

Major Risks (Long-Term Use)

• Cataracts

• Glaucoma

• Hyperglycemia

• Hypertension

• Osteoporosis (systemic therapy)

Conclusion

Immunosuppressants for ophthalmic use are essential in managing autoimmune eye diseases, chronic uveitis, and corneal transplantation. By targeting different stages of T-cell activation—cytokine production, cell proliferation, or receptor signaling—these drugs provide effective immune control while preserving vision. Combination therapy at lower doses is commonly used to maximize efficacy and minimize toxicity.

All immunosuppressive treatments require careful monitoring to balance therapeutic benefits with potential systemic risks.